Paradigm has raised a $203M Series A funding round to reduce barriers for patients to participate in clinical trials.  The company also announced the acquisition of Deep Lens. Paradigm aims to make clinical trials more efficient so that more patients can access critical therapies and physicians have fewer patients to treat. ARCH Venture Partners and General Catalyst led the funding round, with participation from F-Prime Capital, GV, LUX Capital, Mubadala Capital, Magnetic Ventures, and BrightEdge fund. The company aims to use its funding round to expand its partnerships with healthcare providers. Paradigm is based in New York.